Skip to main content

Search

Reset all filters
215 Result(s)
Sort by

FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
Heart Diseases in humans and animals

Heart Diseases in humans and animals

Humans and animals are more alike than different. Having a heart disease can affect us similarly, and the way to prevent it can work for all as well.
equine asthma

equine asthma

Fighting Equine Asthma is a crucial step to improving the well-being of many horses worldwide. The right treatment can make a world of difference.
The power of patient advocacy in cancer care

The power of patient advocacy in cancer care

Larry, a retired US Navy veteran, and Jeff, UICC President, have more in common than a cancer diagnosis: they share a passion for patient empowerment.
We support non-linear career paths.

We support non-linear career paths.

Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
Partnership with Precision Health Research, Singapore

Partnership with Precision Health Research, Singapore

Boehringer Ingelheim joins forces with Precision Health Research, Singapore with the aim of transforming healthcare and improving patient outcomes in Singapore and beyond.
New data for nintedanib in children with fibrosing ILD

New data for nintedanib in children with fibrosing ILD

InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
It Takes 2

It Takes 2

It Takes 2 people – a patient and a HCP, and 2 tests – a blood and a urine test–to help detect CKD. Early testing can drive earlier diagnosis and treatment.
Fast-Track-Designation-NASH

Fast-Track-Designation-NASH

Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
collaboration-LIBD

collaboration-LIBD

Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
BI_PharmAccess_launch_digital_healthcare_program

BI_PharmAccess_launch_digital_healthcare_program

Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
real-world-benefit-shown-in-T2D-treatment

real-world-benefit-shown-in-T2D-treatment

Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
CHMP_opinion_Nintedanib_SSc-ILD

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease